GNA NOW (Gram-Negative Antibiotic NOW) started on July 1st under the AMR Accelerator umbrella and the project kicked off with a meeting on July 4th in Utrecht, where project members met in person for the first time. The project, funded by the Innovative Medicines Initiative (IMI) and industry partner Evotec’s in-kind contributions, aims to operate a consortium of experts, representing all the critical skills and experience required to progress new chemical entities for Gram-negative bacterial infections with the aim to produce two drug candidates and conduct one first-in-human study.
All eleven partners participating in GNA NOW were present at the kick-off meeting, some joining via video-link. An introduction game where participants had to pair profiles with the right names and faces allowed for some good conversations among the participants and insights in each other’s competence right away. It certainly also underlined that this consortium is composed of people burning for combatting antimicrobial resistance.
Participants names and faces pared to corresponding profiles after the introduction game.
Coming together allowed for the consortium to straighten out some question marks, for example around the organization of the enabling platforms and the data infrastructure, on how to source experts to the different advisory committees, and the underlying reasons to extend the project from five years to six.
GNA NOW is off to a great start, with all the partners having now met and ready to find new antibiotics in the fight against antimicrobial resistance.